Phase 1, First in Human (FIH), Open-Label, Single-Arm, Ascending Dose Study to Assess the Safety, Tolerability and Preliminary Immunogenicity of ITI-9001 in Japanese Patients With Japanese Red Cedar (JRC) Pollinosis
Clinical trial NCT07726147 · RECRUITING
Trial details
- NCT number
- NCT07726147
- Sponsor
- Immunomic Therapeutics, Inc.
- Status
- RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2026-06-20
- Primary completion
- 2028-02-01
- Enrollment
- 45
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.